ArticleImmunity, inflammation and disease2026
Identification of Prognostic Values of Neutrophil Extracellular Traps-Related Genes in Glioma Based on Bioinformatics.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundGlioma is a highly invasive and drug-resistant malignant primary tumor. Increasing research is focusing on the function of neutrophil extracellular traps (NETs) in glioma progress. We aimed to explore the mechanism of NETs-related genes (NETs-RGs) in glioma to find potential biomarkers for glioma.
methodsThe GSE16011 data set was downloaded from the GEO database, and the gene expression matrix and clinical data of glioma patients were downloaded from the TCGA database, the cbioportal website, and the CGGA database, as the training and validation sets. The NETs-RGs were obtained from previous studies. Subsequently, differential expression analysis, WGCNA, GO enrichment, and GSEA analysis. The risk model was established for Cox, LASSO, survival, and independent prognostic analyses. The CIBERSORT algorithm was used for immune infiltration analysis, and pRRophetic was used for drug sensitivity analysis. Finally, the expression levels of genes were validated by data set, glioma patients' tissue samples, and glioma cells, and evaluating cell biological behavior.
resultsA total of 57 differential expression genes between Glioma and Normal samples were obtained. Then, two modules with the highest positive correlation with NETs-RGs by WGCNA, the NETs-RGs were obtained from previous studies. Six candidate genes were obtained for subsequent analysis. Then, we conducted functional enrichment of candidate genes and constructed a glioma prognosis model. The prognosis model was indicated as a good predictor of a patient's glioma risk. These genes were related to immune cells significantly. And drug sensitivity analysis predicted 128 differences in chemotherapy drugs and found that MICALL2 had a significant correlation with multiple drugs. Finally, only NFIL3 had the same trend of significantly high expression levels. Moreover, knockdown NFIL3 can inhibit glioma cell malignant growth, and promote apoptosis.
conclusionThree prognosis-related genes have better prognosis values for glioma patients and may be the potential biomarkers for the treatment of glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.